Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B ROTHMAN

Showing results (61-70 of 606) with videos related to

Pageof 61
Sort By:
JAMA|May 21, 2020
How Academic Health Systems Can Move Forward Once COVID-19 WanesSteven D Shapiro, Paul B Rothman
Diabetes, Obesity & Metabolism|September 8, 2011
Phentermine therapy for obesity does not elevate blood pressureE J Hendricks, R B Rothman
Molecular Neurobiology|August 1, 1995
A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909R B Rothman, J R Glowa
The Journal of Clinical Investigation|February 18, 2004
Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cellsDaphne C Tsitoura, Paul B Rothman
Neurochemical Research|November 1, 1982
Interaction of naloxone with the opioid receptor complex in vitroR B Rothman, T C Westfall
Journal of Bacteriology|November 18, 2008
The tail sheath of bacteriophage N4 interacts with the Escherichia coli receptorJennifer McPartland, Lucia B Rothman-Denes
Advances in Immunology|September 17, 2009
Chapter 3: Role of SOCS in allergic and innate immune responsesSuzanne L Cassel, Paul B Rothman
Annals of the New York Academy of Sciences|November 16, 2006
Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugsRichard B Rothman, Michael H Baumann
American Journal of Therapeutics|December 19, 2008
Appetite suppressants, cardiac valve disease and combination pharmacotherapyRichard B Rothman, Michael H Baumann
Expert Opinion on Drug Safety|June 10, 2009
Serotonergic drugs and valvular heart diseaseRichard B Rothman, Michael H Baumann
Pageof 61

Showing results (61-70 of 606) with videos related to

Sort By:
Pageof 61
JAMA|May 21, 2020
How Academic Health Systems Can Move Forward Once COVID-19 WanesSteven D Shapiro, Paul B Rothman
Diabetes, Obesity & Metabolism|September 8, 2011
Phentermine therapy for obesity does not elevate blood pressureE J Hendricks, R B Rothman
Molecular Neurobiology|August 1, 1995
A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909R B Rothman, J R Glowa
The Journal of Clinical Investigation|February 18, 2004
Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cellsDaphne C Tsitoura, Paul B Rothman
Neurochemical Research|November 1, 1982
Interaction of naloxone with the opioid receptor complex in vitroR B Rothman, T C Westfall
Journal of Bacteriology|November 18, 2008
The tail sheath of bacteriophage N4 interacts with the Escherichia coli receptorJennifer McPartland, Lucia B Rothman-Denes
Advances in Immunology|September 17, 2009
Chapter 3: Role of SOCS in allergic and innate immune responsesSuzanne L Cassel, Paul B Rothman
Annals of the New York Academy of Sciences|November 16, 2006
Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugsRichard B Rothman, Michael H Baumann
American Journal of Therapeutics|December 19, 2008
Appetite suppressants, cardiac valve disease and combination pharmacotherapyRichard B Rothman, Michael H Baumann
Expert Opinion on Drug Safety|June 10, 2009
Serotonergic drugs and valvular heart diseaseRichard B Rothman, Michael H Baumann
Pageof 61